1212 related articles for article (PubMed ID: 30546055)
21. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma.
Nallet-Staub F; Marsaud V; Li L; Gilbert C; Dodier S; Bataille V; Sudol M; Herlyn M; Mauviel A
J Invest Dermatol; 2014 Jan; 134(1):123-132. PubMed ID: 23897276
[TBL] [Abstract][Full Text] [Related]
22. Insights into the Regulation of Yap/Taz from Cellular Systems and Mouse Models.
Du W; Du W; Wan M; Zhou X; Xu X; Zheng L
Curr Stem Cell Res Ther; 2018; 13(1):16-25. PubMed ID: 28042766
[TBL] [Abstract][Full Text] [Related]
23. The Hippo pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through Let-7.
Chaulk SG; Lattanzi VJ; Hiemer SE; Fahlman RP; Varelas X
J Biol Chem; 2014 Jan; 289(4):1886-91. PubMed ID: 24324261
[TBL] [Abstract][Full Text] [Related]
24. The Roles of YAP/TAZ and the Hippo Pathway in Healthy and Diseased Skin.
Rognoni E; Walko G
Cells; 2019 May; 8(5):. PubMed ID: 31058846
[TBL] [Abstract][Full Text] [Related]
25. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine.
Nagashima S; Bao Y; Hata Y
Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663
[TBL] [Abstract][Full Text] [Related]
26. Arterial Wall Stress Induces Phenotypic Switching of Arterial Smooth Muscle Cells in Vascular Remodeling by Activating the YAP/TAZ Signaling Pathway.
Wang Y; Cao W; Cui J; Yu Y; Zhao Y; Shi J; Wu J; Xia Z; Yu B; Liu J
Cell Physiol Biochem; 2018; 51(2):842-853. PubMed ID: 30466081
[TBL] [Abstract][Full Text] [Related]
27. Hippo pathway coactivators Yap and Taz are required to coordinate mammalian liver regeneration.
Lu L; Finegold MJ; Johnson RL
Exp Mol Med; 2018 Jan; 50(1):e423. PubMed ID: 29303509
[TBL] [Abstract][Full Text] [Related]
28. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment.
Johnson R; Halder G
Nat Rev Drug Discov; 2014 Jan; 13(1):63-79. PubMed ID: 24336504
[TBL] [Abstract][Full Text] [Related]
29. New insights into YAP/TAZ nucleo-cytoplasmic shuttling: new cancer therapeutic opportunities?
Shreberk-Shaked M; Oren M
Mol Oncol; 2019 Jun; 13(6):1335-1341. PubMed ID: 31050214
[TBL] [Abstract][Full Text] [Related]
30. Hippo-YAP/TAZ signalling coordinates adipose plasticity and energy balance by uncoupling leptin expression from fat mass.
Choi S; Kang JG; Tran YTH; Jeong SH; Park KY; Shin H; Kim YH; Park M; Nahmgoong H; Seol T; Jeon H; Kim Y; Park S; Kim HJ; Kim MS; Li X; Bou Sleiman M; Lee E; Choi J; Eisenbarth D; Lee SH; Cho S; Moore DD; Auwerx J; Kim IY; Kim JB; Park JE; Lim DS; Suh JM
Nat Metab; 2024 May; 6(5):847-860. PubMed ID: 38811804
[TBL] [Abstract][Full Text] [Related]
31. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine.
Dey A; Varelas X; Guan KL
Nat Rev Drug Discov; 2020 Jul; 19(7):480-494. PubMed ID: 32555376
[TBL] [Abstract][Full Text] [Related]
32. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
33. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
Kim M; Kim T; Johnson RL; Lim DS
Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
[TBL] [Abstract][Full Text] [Related]
35. Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer.
Baroja I; Kyriakidis NC; Halder G; Moya IM
Nat Commun; 2024 Mar; 15(1):2700. PubMed ID: 38538573
[TBL] [Abstract][Full Text] [Related]
36. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.
Kim MH; Kim J
Cell Mol Life Sci; 2017 Apr; 74(8):1457-1474. PubMed ID: 27826640
[TBL] [Abstract][Full Text] [Related]
37. Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth.
Koo JH; Plouffe SW; Meng Z; Lee DH; Yang D; Lim DS; Wang CY; Guan KL
Genes Dev; 2020 Jan; 34(1-2):72-86. PubMed ID: 31831627
[TBL] [Abstract][Full Text] [Related]
38. Hippo pathway effector Yap promotes cardiac regeneration.
Xin M; Kim Y; Sutherland LB; Murakami M; Qi X; McAnally J; Porrello ER; Mahmoud AI; Tan W; Shelton JM; Richardson JA; Sadek HA; Bassel-Duby R; Olson EN
Proc Natl Acad Sci U S A; 2013 Aug; 110(34):13839-44. PubMed ID: 23918388
[TBL] [Abstract][Full Text] [Related]
39. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
40. Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice.
Moya IM; Castaldo SA; Van den Mooter L; Soheily S; Sansores-Garcia L; Jacobs J; Mannaerts I; Xie J; Verboven E; Hillen H; Algueró-Nadal A; Karaman R; Van Haele M; Kowalczyk W; De Waegeneer M; Verhulst S; Karras P; van Huffel L; Zender L; Marine JC; Roskams T; Johnson R; Aerts S; van Grunsven LA; Halder G
Science; 2019 Nov; 366(6468):1029-1034. PubMed ID: 31754005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
